Drug Trial Radar · NCT04034134
Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata
Last checked: Nov 19, 2026Latest source record: Nov 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
111
Actual
Start
Nov 18, 2019
Primary completion
Nov 26, 2021
Study completion Nov 26, 2021
Sponsor
- Lead sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Jul 26, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was an open-label, Multi-center, randomized phase Ⅱ study. Patients with severe Alopecia Areata were randomized to receive 50mg bid, 150mg qd or 200 mg qd of oral Jaktinib Hydrochloride Tablets.
Conditions
- Alopecia Areata
Interventions
Jaktinib Hydrochloride TabletsDrug
50 mg twice-daily (BID)
Jaktinib Hydrochloride TabletsDrug
150 mg quaque die (QD)
Jaktinib Hydrochloride TabletsDrug
200 mg quaque die (QD)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effective rateTime frame: From randomization of the first subject until the last subject complete 6 months treatment
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Chongqing Chinese Traditional Medicine Hospital
Chongqing, Chongqing Municipality, China
The second xaingya hospital of central south university
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.